Use this URL to cite or link to this record in EThOS: http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.653597
Title: Epidemiology of pneumoccocal disease in Scotland : implications for vaccine prevention policies and strategies
Author: Kyaw, M. H.
Awarding Body: University of Edinburgh
Current Institution: University of Edinburgh
Date of Award: 2003
Availability of Full Text:
Full text unavailable from EThOS. Please contact the current institution’s library for further details.
Abstract:
Methods: Review of laboratory data collected through a national network of diagnostic laboratories covering the entire population of Scotland, was reviewed to examine the epidemiological characteristics of pneumococcal disease. Cross-sectional surveys were conducted to explore pneumococcal polysaccharide vaccination practices. Results: The incidence of invasive pneumococcal disease is highest in young children aged less than 2 years (44.9/105 persons) and in the elderly aged 65 years and above (28.4/105) persons. The incidence of pneumococcal meningitis is highest in children aged less than 2 years (11.8/105 persons). There was a 3-fold increase in the prevalence of penicillin (from 4.2% in 1992 to 12.6% in 1999) and erythromycin (from 5.6% in 1994 to 16.3% in 1999) non-susceptible pneumococcal isolates. Regional differences in the prevalence of antibiotic non-susceptible pneumococci correlated weakly with the rate of penicillin prescription, but not with erythromycin prescription.  Pneumococci are the leading cause of invasive non-meningeal bacterial disease and the second leading cause of bacterial meningitis in Scotland after introduction of Hib conjugate vaccine in the national vaccination programme. The formulation of current pneumococcal polysaccharide vaccine covers the serotypes responsible for the majority of invasive and non-invasive disease in Scotland. Coverage of invasive and non-invasive serotypes by pneumococcal conjugate vaccines was substantially higher in younger age groups (5 years and less) than in older aged groups. All polysaccharide and conjugate pneumococcal vaccines cover nearly all serotypes associated with invasive and non-invasive resistant pneumococcal disease. General practitioners and hospital doctors have an adequate knowledge of pneumococcal polysaccharide vaccination.
Supervisor: Not available Sponsor: Not available
Qualification Name: Thesis (Ph.D.) Qualification Level: Doctoral
EThOS ID: uk.bl.ethos.653597  DOI: Not available
Share: